Can Keytruda Sustain Merck's Growth Through the Rest of 2025?
MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.
If You're in Your 30s, Consider Buying These 2 Healthcare Stocks
Both companies have helped pioneer important medical breakthroughs.
UnitedHealth's Best Day Since 2008, Intel's Best Week Since 1975 - SPDR S&P 500 ( ARCA:SPY )
Major U.S. indices ease from record highs as investors awaited the Trump-Putin meeting and digested weaker consumer sentiment. Dow Jones gained 0.2% above 45,000, lifted by a pharma rally led by UnitedHealth's 14% jump on Berkshire Hathaway stake.
Vaxart Revenue Jumps 520% in Fiscal Q2
Vaxart ( OTC:VXRT ) , a biotechnology company focused on developing oral tablet vaccines for infectious diseases, reported its second quarter results on August 13, 2025. The standout headline was a revenue surge to $39.7 million ( GAAP ) -well above the $2.03 million analyst consensus-driven by a ...
Moderna Options Trading: A Deep Dive into Market Sentiment - Moderna ( NASDAQ:MRNA )
Investors with a lot of money to spend have taken a bullish stance on Moderna MRNA. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Gauzy Ltd. Announces Second Quarter 2025 Results
Record Backlog Purchase Orders of $42.9 Million at Quarter End ...
Immatics Announces Second Quarter 2025 Financial Results and Business Update
Houston, Texas and Tuebingen, Germany, August 13, 2025 - Immatics N.V. ( NASDAQ: IMTX, "Immatics" or the "Company" ) , a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today provided a business update and reported financial results for the quarter ...
Generation Bio Posts 81% Q2 Revenue Drop
Generation Bio ( NASDAQ:GBIO ) , a biotechnology firm developing cell-targeted siRNA therapeutics for autoimmune diseases, released its second quarter earnings on August 12, 2025. The main news was a deeper-than-expected net loss ( GAAP ) and a steep drop in collaboration revenue, alongside the ...
FDA may pull authorization of Pfizer's Covid vaccine for children under 5
The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots against Covid.
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )
CDC shooter's writings revealed anti-vaccine beliefs and distrust of COVID-19 shots. The NIH chief says that mRNA vaccines lack viability due to public distrust. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday → A group of former U.S.
What's Driving the Market Sentiment Around Moderna? - Moderna ( NASDAQ:MRNA )
Moderna's MRNA short percent of float has fallen 4.88% since its last report. The company recently reported that it has 63.02 million shares sold short, which is 22.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.24 days to cover ...
Is Invesco S&P 500 Equal Weight Health Care ETF ( RSPH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply - Moderna ( NASDAQ:MRNA ) , Pfizer ( NYSE:PFE )
Only 5.6% of children aged 6 months to 4 years old are vaccinated against COVID-19, CDC says. The FDA may not renew Pfizer's pediatric COVID-19 vaccine authorization for the 2025 season. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off →
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.
Global Cancer Vaccines Market to Surpass USD 15.00 Billion by 2032, Unlocking Over USD 10 Billion in New Growth Opportunities | MarketsandMarkets™.
Delray Beach, FL, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- The global cancer vaccines market is on track to nearly double over the next decade, climbing from USD 9.84 billion in 2024 to USD 15.00 billion by 2032 at a CAGR of 5.4%, according to MarketsandMarkets™.
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Cabaletta Bio ( NASDAQ:CABA ) , Moderna ( NASDAQ:MRNA )
Vinay Prasad returns as FDA's CBER head days after resigning amid Sarepta drug controversy. Analysts see a possible softer stance on rare disease therapies under Prasad. Get ahead of next week's CPI & PPI with Chris Capre's live trading strategy session this Sunday. Register Now →
The 3 Things That Matter for Moderna Now
The company is still trying to prove that it isn't just a pandemic play.
CytomX ( CTMX ) Q2 Revenue Drops 26%
CytomX Therapeutics ( NASDAQ:CTMX ) , a biotechnology company focused on developing targeted oncology therapies, reported its second quarter 2025 results on August 7, 2025. In the period, the most significant developments included a year-over-year decline in GAAP revenue, improvements in cost ...
Novavax ( NVAX ) Profit Jumps on Milestone
Novavax ( NASDAQ:NVAX ) , known for its protein-based vaccine technology, released its second quarter fiscal 2025 results on August 6, 2025. The standout news was a return to profitability on a GAAP basis, driven by significant partnership milestone payments, most notably a $175 million payment ...
Arbutus ( ABUS ) Q2 Revenue Surges 529%
Arbutus Biopharma ( NASDAQ:ABUS ) , a biotechnology firm focused on treatments for chronic hepatitis B and RNA-based medicines, delivered GAAP results for Q2 2025 that greatly outpaced analyst expectations. The August 6, 2025 release showed GAAP revenue of $10.7 million, far above the $1.59 ...
Check Out What Whales Are Doing With MRNA - Moderna ( NASDAQ:MRNA )
Investors with a lot of money to spend have taken a bullish stance on Moderna MRNA. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to ...
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week ( July 28-August 1 ) : Are The Others In Your Portfolio? - ATI ( NYSE:ATI ) , Baxter Intl ( NYSE:BAX )
Novo Nordisk plunged 31% after slashing its 2025 sales outlook. UPS, Moderna, and Coinbase dropped on weak Q2 results and guidance. The next correction is closer than you think. Find out how Tom Gentile plans to trade it, live on Wednesday. These ten large-cap stocks were the worst performers ...
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.
Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector - Novavax ( NASDAQ:NVAX )
Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Unpacking the Latest Options Trading Trends in Moderna - Moderna ( NASDAQ:MRNA )
Investors with a lot of money to spend have taken a bullish stance on Moderna MRNA. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Why Is Moderna Stock Falling Friday? - Moderna ( NASDAQ:MRNA )
Moderna posted a Q2 loss of $2.13 per share, beating the $ ( 2.98 ) estimate and improving from $ ( 3.33 ) a year ago. Q2 revenue hit $142 million, topping expectations but down 41% from 2024 due to falling COVID-19 vaccine sales.
Moderna ( MRNA ) Reports Q2 Loss, Beats Revenue Estimates
Moderna (MRNA) delivered earnings and revenue surprises of +28.76% and +11.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.
Moderna also lost less than Wall Street analysts were expecting for the second quarter and posted revenue that topped estimates.
Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Moderna, Inc. MRNA will release earnings results for the second quarter, after the closing bell on Friday, Aug. 1. Analysts expect the Cambridge, Massachusetts-based company to report quarterly loss at $2.97 per share, versus a year-ago loss of $3.33 per share.
Moderna Announces 10% Workforce Cut Amid Declining COVID-19 Vaccine Sales, Regulatory Hurdles - Moderna ( NASDAQ:MRNA )
Moderna Inc. MRNA has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started
Bristol Myers Squibb ( BMY ) Q2 Earnings and Revenues Top Estimates
Bristol Myers (BMY) delivered earnings and revenue surprises of +36.45% and +7.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow
In a memo to employees, Moderna CEO Stephane Bancel said the company expects to have fewer than 5,000 workers by the end of the year.
Pandemic darlings Moderna, BioNTech are now on two different paths
The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find themselves on different paths.
Elis: H1 2025 results
Elis delivers very solid H1 2025 results ...
Curious about Moderna ( MRNA ) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Moderna (MRNA) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Earnings Preview: Castle Biosciences, Inc. ( CSTL ) Q2 Earnings Expected to Decline
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down 74% Over the Past Year, Is Moderna Stock a Buy?
In the short term, Moderna ( NASDAQ: MRNA ) looks like a bad bet. It's coming off of the momentum of its COVID-19 vaccine, and doesn't have a lot of new ammo ready yet to expand in new directions. I think the stock might stay low for quite a while.
Biotech Is Booming, and This Undervalued REIT Stands to Gain
While most commercial office landlords are still hunting for post‑pandemic tenants, there's a sector of the real estate industry that's breeding breakout growth: life sciences. Global biotech spending is projected to triple from roughly $1.7 trillion in 2025 to more than $5 trillion by 2034.
Market Whales and Their Recent Bets on MRNA Options - Moderna ( NASDAQ:MRNA )
Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna. Looking at options history for Moderna MRNA we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 33% ...
Moderna ( MRNA ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
Moderna ( MRNA ) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Moderna (MRNA) closed at $34.01, marking a -1.9% move from the previous day.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF ( RSPH ) ?
Sector ETF report for ...
What's Going On With Moderna Stock Wednesday? - Moderna ( NASDAQ:MRNA )
Moderna's stock is up ~7% today and ~37% over the last month despite being down 15% YTD. Moderna's flu vaccine mRNA-1010 showed 26.6% efficacy over standard flu shots in older adults. A new wave of value and momentum stocks could be setting up for major moves-and Tim Melvin will name them live ...
Healthy Returns: Researchers move closer to a universal cancer vaccine
University of Florida researchers said a new study could lead to a universal cancer shot, while digital health earnings season is approaching.
Here's Why Moderna ( MRNA ) Fell More Than Broader Market
In the most recent trading session, Moderna (MRNA) closed at $31.25, indicating a -2.95% shift from the previous trading day.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
